首页> 外文期刊>Pharmacoepidemiology and drug safety >Trends in opioid utilisation in Australia, 2006‐2015: Insights from multiple metrics
【24h】

Trends in opioid utilisation in Australia, 2006‐2015: Insights from multiple metrics

机译:澳大利亚阿片类药物利用趋势,2006 - 2015年:多元指标的见解

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Abstract Purpose Population‐based observational studies have documented global increases in opioid analgesic use. Many studies have used a single population‐adjusted metric (number of dispensings, defined daily doses [DDDs], or oral morphine equivalents [OMEs]). We combine these volume‐based metrics with a measure of the number of persons dispensed opioids to gain insights into Australian trends in prescribed opioid use. Methods We obtained records of prescribed opioid dispensings (2006‐2015) subsidised under Australia's Pharmaceutical Benefits Scheme. We used dispensing claims to quantify annual changes in use according to 3 volume‐based metrics: DDD/1000 pop/day, OME/1000 pop/day, and dispensings/1000 pop. We estimated the number of persons dispensed at least one opioid in a given year (persons)/1000 pop using data from a 10% random sample of Pharmaceutical Benefits Scheme‐eligible Australians. Results Total opioid use increased according to all metrics, especially OME/1000 pop/day (51% increase) and dispensings/1000 pop (44%). Weaker opioid use remained stable or declined; strong opioid use increased. The rate of persons accessing weaker opioids only decreased 31%, and there was a 238% increase in persons dispensed only strong opioids. Strong opioid use also increased according to dispensings/1000 pop (140%), OME/1000 pop/day (80%), and DDD/1000 pop/day (71% increase). Conclusions Our results suggest that the increases in total opioid use between 2006 and 2015 were predominantly driven by a growing number of people treated with strong opioids at lower medicine strengths/doses. This method can be used with or without person‐level data to provide insights into factors driving changes in medicine use over time.
机译:摘要目的基于人口的观察研究已经记录了阿片类药物镇痛使用的全局增加。许多研究使用了单一的人口调整后的公制(分配的数量,定义的每日剂量[DDDS],或口服吗啡等价物[omes])。我们将这些基于批量的指标与分配的阿片类药物的衡量标准相结合,以便在规定的阿片类药物使用中获得澳大利亚趋势的洞察力。方法我们获得了根据澳大利亚药物福利计划补贴的规定阿片类药物(2006-2015)的记录。我们使用豁免声称根据3个基于3卷的度量来量化使用的年度变化:DDD / 1000 POP / DAY,OME / 1000 POP / DATE和DISPSUNSINGS / 1000 POP。我们估计人数在给定年份(人)/ 1000流行中,使用来自10%随机的药物福利计划计划符合条件的澳大利亚人的数据,分配了至少一个阿片类药物。结果各种指标,特别是OME / 1000流行/日(增加51%)和分配/ 1000流行(44%)的总产量增加。较弱的阿片类药物使用仍然稳定或下降;强烈的阿片类药物使用增加。进出较弱的阿片类药物的人们只减少了31%,而且只有238%的人口增加,只有强烈的阿片类药物。根据分配/ 1000流行(140%),OME / 1000 POP /日(80%)和DDD / 1000流行/日(71%增加),强大的阿片类药物也使用增加(140%)。结论我们的研究结果表明,2006年至2015年期间,2006年至2015年之间的总产量增加主要是由于较低药物强度/剂量治疗的越来越多的人群越来越多的人。该方法可以与或没有人级数据一起使用,以便在推动医学使用变化的因素时提供洞察。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号